Clinical trials: Prostate Calcification
Prostate Cancer
Maintaining Bone Strength in Men With Prostate Cancer
The purpose of this study is to see if giving zoledronic acid three times a year is as effective as five times a year, in increasing bone strength in men with prostate cancer.
- Trial name
- NCT00391950
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis
Prostatic Neoplasms
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment to improve overall survival for intermediate- and high-risk localized disease as well as metastatic disease.
- Trial name
- NCT04248621
- Testing
- Leuprorelin, Goserelin, Triptorelin
- Where
- 10 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Wonju Severance Christian Hospital
Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma.
- Trial name
- NCT00582556
- Testing
- Zometa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer, Osteoporosis
Prevention of Osteoporosis in Men With Prostate Cancer
The purpose of this two year study is to examine the safety and effectiveness of alendronate (Fosamax) for the prevention of bone loss in men with prostate cancer who are on therapy to lower their testosterone levels.
- Conditions
- Prostate Cancer, Osteoporosis, Hypogonadism
- Trial name
- NCT00048841
- Testing
- alendronate
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prostate Cancer
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
The purpose of this study is to compare the effect of an investigational drug used intravenously and placebo administered every three months for one year, on bone loss associated with initial androgen deprivation) in men with…
- Trial name
- NCT00063609
- Testing
- zoledronic acid
- Where
- 44 sites in United States
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
The aim of this phase IV interventional study is to evaluate variation in bone mineral density and lean and fat body composition in patients with prostate cancer without bone metastasis, treated with Degarelix.
- Trial name
- BLADE (NCT03202381)
- Testing
- Degarelix
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Prostatic Neoplasms
Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer
- Trial name
- NCT00551044
- Testing
- Bicalutamide
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Prostate Cancer
Strategies to Improve Bone Health in Men on ADT
This is a phase II randomized controlled trial (RCT) of 2 strategies to improve bone health in men receiving androgen deprivation therapy (ADT).
- Trial name
- NCT02043236
- Testing
- Healthy bones pamphlet, Bone Health Care Coordinator, Letter to GP
- Where
- Canada
- Volunteers
- 159 people
- Sponsor
- University Health Network, Toronto
Prostatic Carcinoma
Imaging of High Grade Prostate Cancer
Management of prostatic carcinoma varies according to stage of disease. Trans-rectal ultrasound guided biopsy is known to underestimate the degree of tumor due to undersampling and random non-targeted technique.
- Trial name
- NCT02177526
- Testing
- Imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
Prostate cancer patients treated with LHRH agonists (e.g., leuprolide) lose bone mineral density. This is similar to post-menopausal osteoporosis. Risedronate is approved to prevent osteoporosis.
- Trial name
- NCT00426777
- Testing
- risedronate, Control
- Where
- 21 sites in Canada
- Volunteers
- 160 people
- Sponsor
- CMX Research
Osteoporosis, Prostate Cancer
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future.
- Trial name
- NCT00176579
- Testing
- dual x-ray absorptiometry
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Bone Mineral Density Quantitative Trait Locus 3
High-dose Vitamin D Supplementation for ADT-induced Side Effects
The purpose of this study is to test the efficacy of a high-dose vitamin D supplementation regimen in reducing androgen deprivation therapy (ADT)-related side effects in older prostate cancer patients on ADT.
- Trial name
- NCT02064946
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Rochester
Prostate Cancer
High Impact Training to Patients with Prostate Cancer and Bone Metastases
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases.
- Trial name
- HIP (NCT06259279)
- Testing
- High intensity high impact exercise intervention
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Copenhagen University Hospital at Herlev
Osteoporosis
Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.
- Trial name
- NCT00536653
- Testing
- Bicalutamide and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate)
- Where
- United Kingdom
- Volunteers
- 618 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
- Trial name
- NCT01303692
- Where
- 2 sites in South Korea
- Volunteers
- 312 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
Prostate Calcification
MR Imaging of Prostatic Calcifications
Prostate calcifications can limit evaluation of the prostate due to artifact on MRI, and can limit therapy by blocking therapeutic ultrasound.
- Trial name
- NCT03625336
- Testing
- MRI
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen